Screening of first degree relatives of patients operated for colorectal cancer: Evaluation of fecal calprotectin vs. Hemoccult II

Digestion

Volumn 64, Issue 2, 2001, Pages 104-110

  Kristinsson, Jon ^a   Nygaard, K ^a   Aadland, E ^b   Barstad, S ^c   Sauar, J ^d   Hofstad, B ^f   Stray, N ^g   Stallemo, A ^e   Haug, B ^e   Ugstad, M ^h   Ton H ^h   Fuglerud, P ⁱ  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b AKER UNIVERSITY HOSPITAL   (Norway)

^c STAVANGER UNIVERSITY HOSPITAL   (Norway)

^d Telemark Hospital   (Norway)

^e Departments of Medicine   (Norway)

^f ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^g Deacon Hospital   (Norway)

^h ALTANA PHARMA AG   (Germany)

ⁱ Medstat Research A/S   (Norway)

Author keywords

Adenoma; Calprotectin; Colorectal carcinoma; Hemoccult II; Polyps; Screening

Indexed keywords

CALPROTECTIN;

ADENOMA; ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER SCREENING; CANCER STAGING; CANCER SURGERY; COLON ADENOMA; COLONOSCOPY; COLORECTAL CARCINOMA; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; ENZYME LINKED IMMUNOSORBENT ASSAY; FECES ANALYSIS; HUMAN; INTESTINE POLYP; MAJOR CLINICAL STUDY; OCCULT BLOOD; PREVALENCE; PRIORITY JOURNAL; PROTEIN ANALYSIS; RECTUM ADENOMA; RECTUM POLYP; RELATIVE;

ADENOMA; AGED; ANTIFUNGAL AGENTS; COLON; COLONIC POLYPS; COLONOSCOPY; COLORECTAL NEOPLASMS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FECES; FEMALE; HUMANS; LEUKOCYTE L1 ANTIGEN COMPLEX; MALE; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; NEOPLASM STAGING; NEURAL CELL ADHESION MOLECULES; OCCULT BLOOD; PROSPECTIVE STUDIES; RECTUM; REFERENCE VALUES; SENSITIVITY AND SPECIFICITY;

EID: 18444405254     PISSN: 00122823     EISSN: None     Source Type: Journal    
DOI: 10.1159/000048848     Document Type: Article

References (26)

1. Endoscopic screening of relatives of patients with colorectal cancer
2. Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota Colon Cancer Control Study
3. Randomised study of screening for colorectal cancer with faecal-occult-blood test
4. Randomised controlled trial of faecal-occult-blood screening for colorectal cancer
5. Fecal calprotectin concentration in patients with colorectal carcinoma
6. Faecal calprotectin: A novel test for the diagnosis of colorectal cancer?
7. Fecal marker variability in colorectal cancer: Calprotectin versus hemoglobin
8. A stool collection device: The first step in occult blood testing
9. Assessment of the neutrophil dominating protein calprotectin in feces. A methodologic study
10. Precancerous and early malignant lesions of the large intestine
11. Variables associated with the risk of colorectal adenomas in asymptomatic patients with a family history of colorectal cancer
12. Colonoscopy in patients with a primary family history of colon cancer
13. Heredity and colorectal cancer. A prospective, community-based, endoscopic study
14. Colonoscopic screening examination of relatives of patients with colorectal cancer. I. A comparison with an endoscopically screened normal population
15. Colonoscopic screening examination of relatives of patients with colorectal cancer. II. Relations between tumour characteristics and the presence of polyps
16. Colonoscopic screening of people with suspected risk factors for colon cancer
17. Risk of colorectal cancer in adenoma-bearing individuals within a defined population
18. Management of colorectal polyps: Is all the effort worthwhile?
19. The polyp-cancer sequence in the large bowel
20. Polypectomy of adenomas in the prevention of colorectal cancer: 10 years' follow-up of the Telemark Polyp Study I. A prospective, controlled population study
21. Dysplasia-carcinoma sequence types of adenoma and early colorectal carcinoma
22. Accuracy of fecal occult blood screening for colorectal neoplasia. A prospective study using Hemoccult and HemoQuant tests
23. Faecal calprotectin levels in a high risk population for colorectal neoplasia
24. Fecal excretion of calprotectin in colorectal cancer. Relationship to tumor characteristics